Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $857000.0.

  • Madrigal Pharmaceuticals' Capital Expenditures rose 1001.28% to $857000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 5432.05%. This contributed to the annual value of $1.5 million for FY2024, which is 114.94% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Capital Expenditures stood at $857000.0, which was up 1001.28% from $195000.0 recorded in Q4 2024.
  • Madrigal Pharmaceuticals' 5-year Capital Expenditures high stood at $1.0 million for Q4 2023, and its period low was $2000.0 during Q2 2021.
  • In the last 5 years, Madrigal Pharmaceuticals' Capital Expenditures had a median value of $103000.0 in 2022 and averaged $248470.6.
  • In the last 5 years, Madrigal Pharmaceuticals' Capital Expenditures tumbled by 8598.73% in 2021 and then skyrocketed by 505000.0% in 2022.
  • Over the past 5 years, Madrigal Pharmaceuticals' Capital Expenditures (Quarter) stood at $113000.0 in 2021, then plummeted by 74.34% to $29000.0 in 2022, then surged by 3472.41% to $1.0 million in 2023, then plummeted by 81.18% to $195000.0 in 2024, then surged by 339.49% to $857000.0 in 2025.
  • Its last three reported values are $857000.0 in Q3 2025, $195000.0 for Q4 2024, and $779000.0 during Q3 2024.